S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:OYST

Oyster Point Pharma Competitors

$20.44
-0.56 (-2.67 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$20.04
Now: $20.44
$21.15
50-Day Range
$17.92
MA: $21.17
$25.86
52-Week Range
$17.24
Now: $20.44
$39.21
Volume99,254 shs
Average Volume99,901 shs
Market Capitalization$529.60 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.38

Competitors

Oyster Point Pharma (NASDAQ:OYST) Vs. KYMR, BCRX, BLUE, VCEL, SRRK, and OCGN

Should you be buying OYST stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Oyster Point Pharma, including Kymera Therapeutics (KYMR), BioCryst Pharmaceuticals (BCRX), bluebird bio (BLUE), Vericel (VCEL), Scholar Rock (SRRK), and Ocugen (OCGN).

Oyster Point Pharma (NASDAQ:OYST) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Earnings and Valuation

This table compares Oyster Point Pharma and Kymera Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oyster Point PharmaN/AN/A$-45,710,000.00($9.97)-2.05
Kymera TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Oyster Point Pharma and Kymera Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Oyster Point PharmaN/A-39.61%-37.68%
Kymera TherapeuticsN/AN/AN/A

Institutional & Insider Ownership

70.2% of Oyster Point Pharma shares are owned by institutional investors. Comparatively, 37.8% of Kymera Therapeutics shares are owned by institutional investors. 36.9% of Oyster Point Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and price targets for Oyster Point Pharma and Kymera Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oyster Point Pharma00103.00
Kymera Therapeutics02402.67

Oyster Point Pharma presently has a consensus price target of $50.00, suggesting a potential upside of 144.62%. Kymera Therapeutics has a consensus price target of $50.3333, suggesting a potential upside of 9.75%. Given Oyster Point Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Oyster Point Pharma is more favorable than Kymera Therapeutics.

Summary

Oyster Point Pharma beats Kymera Therapeutics on 4 of the 7 factors compared between the two stocks.

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Oyster Point Pharma (NASDAQ:OYST) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitability and earnings.

Analyst Recommendations

This is a summary of recent ratings and target prices for BioCryst Pharmaceuticals and Oyster Point Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioCryst Pharmaceuticals03802.73
Oyster Point Pharma00103.00

BioCryst Pharmaceuticals presently has a consensus target price of $11.3750, suggesting a potential upside of 4.17%. Oyster Point Pharma has a consensus target price of $50.00, suggesting a potential upside of 144.62%. Given Oyster Point Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Oyster Point Pharma is more favorable than BioCryst Pharmaceuticals.

Risk & Volatility

BioCryst Pharmaceuticals has a beta of 3.03, meaning that its share price is 203% more volatile than the S&P 500. Comparatively, Oyster Point Pharma has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500.

Insider & Institutional Ownership

72.0% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 70.2% of Oyster Point Pharma shares are held by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 36.9% of Oyster Point Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares BioCryst Pharmaceuticals and Oyster Point Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioCryst Pharmaceuticals-233.45%-328.70%-71.11%
Oyster Point PharmaN/A-39.61%-37.68%

Earnings & Valuation

This table compares BioCryst Pharmaceuticals and Oyster Point Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioCryst Pharmaceuticals$48.83 million39.70$-108,900,000.00($0.94)-11.62
Oyster Point PharmaN/AN/A$-45,710,000.00($9.97)-2.05

Oyster Point Pharma has lower revenue, but higher earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Oyster Point Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Oyster Point Pharma beats BioCryst Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

bluebird bio (NASDAQ:BLUE) and Oyster Point Pharma (NASDAQ:OYST) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for bluebird bio and Oyster Point Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
bluebird bio013402.24
Oyster Point Pharma00103.00

bluebird bio presently has a consensus price target of $68.4667, indicating a potential upside of 145.05%. Oyster Point Pharma has a consensus price target of $50.00, indicating a potential upside of 144.62%. Given bluebird bio's higher probable upside, equities analysts plainly believe bluebird bio is more favorable than Oyster Point Pharma.

Volatility & Risk

bluebird bio has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Comparatively, Oyster Point Pharma has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500.

Institutional and Insider Ownership

94.3% of bluebird bio shares are owned by institutional investors. Comparatively, 70.2% of Oyster Point Pharma shares are owned by institutional investors. 3.6% of bluebird bio shares are owned by company insiders. Comparatively, 36.9% of Oyster Point Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares bluebird bio and Oyster Point Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
bluebird bio-256.84%-45.78%-35.14%
Oyster Point PharmaN/A-39.61%-37.68%

Earnings and Valuation

This table compares bluebird bio and Oyster Point Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bluebird bio$44.67 million42.00$-789,610,000.00($14.31)-1.95
Oyster Point PharmaN/AN/A$-45,710,000.00($9.97)-2.05

Oyster Point Pharma has lower revenue, but higher earnings than bluebird bio. Oyster Point Pharma is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Summary

bluebird bio beats Oyster Point Pharma on 7 of the 13 factors compared between the two stocks.

Vericel (NASDAQ:VCEL) and Oyster Point Pharma (NASDAQ:OYST) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Volatility and Risk

Vericel has a beta of 3.11, suggesting that its stock price is 211% more volatile than the S&P 500. Comparatively, Oyster Point Pharma has a beta of -0.38, suggesting that its stock price is 138% less volatile than the S&P 500.

Insider & Institutional Ownership

93.1% of Vericel shares are owned by institutional investors. Comparatively, 70.2% of Oyster Point Pharma shares are owned by institutional investors. 4.3% of Vericel shares are owned by company insiders. Comparatively, 36.9% of Oyster Point Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Vericel and Oyster Point Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vericel0.12%0.13%0.10%
Oyster Point PharmaN/A-39.61%-37.68%

Analyst Recommendations

This is a summary of current recommendations and price targets for Vericel and Oyster Point Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vericel02602.75
Oyster Point Pharma00103.00

Vericel currently has a consensus price target of $49.00, indicating a potential upside of 21.26%. Oyster Point Pharma has a consensus price target of $50.00, indicating a potential upside of 144.62%. Given Oyster Point Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Oyster Point Pharma is more favorable than Vericel.

Earnings & Valuation

This table compares Vericel and Oyster Point Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vericel$117.85 million15.76$-9,660,000.00$0.18224.50
Oyster Point PharmaN/AN/A$-45,710,000.00($9.97)-2.05

Vericel has higher revenue and earnings than Oyster Point Pharma. Oyster Point Pharma is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Summary

Vericel beats Oyster Point Pharma on 9 of the 13 factors compared between the two stocks.

Scholar Rock (NASDAQ:SRRK) and Oyster Point Pharma (NASDAQ:OYST) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Analyst Ratings

This is a summary of recent recommendations for Scholar Rock and Oyster Point Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Scholar Rock00503.00
Oyster Point Pharma00103.00

Scholar Rock currently has a consensus price target of $61.60, suggesting a potential upside of 21.74%. Oyster Point Pharma has a consensus price target of $50.00, suggesting a potential upside of 144.62%. Given Oyster Point Pharma's higher probable upside, analysts clearly believe Oyster Point Pharma is more favorable than Scholar Rock.

Insider and Institutional Ownership

61.9% of Scholar Rock shares are owned by institutional investors. Comparatively, 70.2% of Oyster Point Pharma shares are owned by institutional investors. 24.6% of Scholar Rock shares are owned by insiders. Comparatively, 36.9% of Oyster Point Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Scholar Rock has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Oyster Point Pharma has a beta of -0.38, meaning that its stock price is 138% less volatile than the S&P 500.

Earnings & Valuation

This table compares Scholar Rock and Oyster Point Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scholar Rock$20.49 million83.07$-51,000,000.00($1.85)-27.35
Oyster Point PharmaN/AN/A$-45,710,000.00($9.97)-2.05

Oyster Point Pharma has lower revenue, but higher earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Oyster Point Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Scholar Rock and Oyster Point Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Scholar Rock-365.84%-80.16%-41.33%
Oyster Point PharmaN/A-39.61%-37.68%

Summary

Oyster Point Pharma beats Scholar Rock on 8 of the 12 factors compared between the two stocks.

Oyster Point Pharma (NASDAQ:OYST) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and earnings.

Profitability

This table compares Oyster Point Pharma and Ocugen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Oyster Point PharmaN/A-39.61%-37.68%
OcugenN/A-47.72%-30.78%

Volatility & Risk

Oyster Point Pharma has a beta of -0.38, suggesting that its share price is 138% less volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.56, suggesting that its share price is 256% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Oyster Point Pharma and Ocugen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oyster Point Pharma00103.00
Ocugen01302.75

Oyster Point Pharma currently has a consensus price target of $50.00, suggesting a potential upside of 144.62%. Ocugen has a consensus price target of $4.80, suggesting a potential downside of 46.49%. Given Oyster Point Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Oyster Point Pharma is more favorable than Ocugen.

Institutional and Insider Ownership

70.2% of Oyster Point Pharma shares are owned by institutional investors. Comparatively, 8.5% of Ocugen shares are owned by institutional investors. 36.9% of Oyster Point Pharma shares are owned by insiders. Comparatively, 3.5% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Oyster Point Pharma and Ocugen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oyster Point PharmaN/AN/A$-45,710,000.00($9.97)-2.05
OcugenN/AN/A$-20,240,000.00($1.48)-6.06

Ocugen is trading at a lower price-to-earnings ratio than Oyster Point Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Oyster Point Pharma beats Ocugen on 6 of the 11 factors compared between the two stocks.


Oyster Point Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$45.86-1.9%$2.04 billionN/A0.00
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.92-8.7%$1.94 billion$48.83 million-14.37
bluebird bio logo
BLUE
bluebird bio
1.8$27.94-5.0%$1.88 billion$44.67 million-2.54Analyst Report
Vericel logo
VCEL
Vericel
1.5$40.41-4.2%$1.86 billion$117.85 million-4,041,000.00Analyst Report
Analyst Revision
Scholar Rock logo
SRRK
Scholar Rock
1.3$50.60-1.7%$1.70 billion$20.49 million-21.00Upcoming Earnings
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.97-16.6%$1.69 billionN/A-6.06Analyst Report
Unusual Options Activity
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$39.07-2.5%$1.68 billionN/A0.00
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.23-0.3%$1.61 billion$102.43 million-18.72Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.65-16.2%$1.59 billionN/A-48.41Earnings Announcement
Analyst Upgrade
Analyst Revision
Translate Bio logo
TBIO
Translate Bio
1.4$21.29-0.8%$1.58 billion$7.80 million-19.90Upcoming Earnings
Analyst Revision
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$32.30-1.3%$1.50 billionN/A-18.25News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.21-2.4%$1.47 billion$35.23 million-15.81Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.42-8.4%$1.38 billion$100.56 million0.00Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$15.89-0.4%$1.33 billionN/A-3.44Earnings Announcement
Analyst Upgrade
Analyst Revision
Alector logo
ALEC
Alector
1.3$16.25-1.0%$1.29 billion$21.22 million-7.29Analyst Upgrade
Immunovant logo
IMVT
Immunovant
1.8$13.08-7.0%$1.28 billionN/A-10.14Increase in Short Interest
PCVX
Vaxcyte
1.8$23.62-9.4%$1.20 billionN/A0.00Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.25-1.2%$1.11 billion$356.07 million7.47Analyst Report
Mesoblast logo
MESO
Mesoblast
1.4$9.18-0.3%$1.08 billion$32.16 million-10.43Earnings Announcement
Analyst Upgrade
Analyst Revision
Cortexyme logo
CRTX
Cortexyme
1.3$36.37-3.2%$1.07 billionN/A-15.15Earnings Announcement
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$10.96-3.1%$1.07 billion$250,000.00-8.63Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$26.56-9.9%$1.00 billionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25-1.6%$903.15 million$69.89 million-4.59
Passage Bio logo
PASG
Passage Bio
1.9$19.43-2.7%$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40-7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73-8.0%$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40-10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83-12.0%$533.77 millionN/A-4.29Upcoming Earnings
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$11.45-6.7%$519.76 million$147.87 million-3.80Analyst Upgrade
Gap Up
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.59-1.8%$513.21 million$4.36 million-4.75Upcoming Earnings
Increase in Short Interest
HARP
Harpoon Therapeutics
1.5$19.14-4.3%$485.77 million$5.78 million-8.99Upcoming Earnings
News Coverage
Gap Up
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.43-2.8%$476.93 millionN/A0.00Upcoming Earnings
Opthea logo
OPT
Opthea
1.5$9.35-7.0%$394.65 millionN/A0.00Decrease in Short Interest
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$19.75-0.0%$384.69 million$340,000.00-6.98
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.